<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474303</url>
  </required_header>
  <id_info>
    <org_study_id>OPP1084414</org_study_id>
    <nct_id>NCT02474303</nct_id>
  </id_info>
  <brief_title>Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal</brief_title>
  <official_title>A Demonstration Project of HIV Pre-exposure Prophylaxis (PrEP) With Tenofovir DF/Emtricitabine (TDF/FTC Among Female Sex Workers in Dakar, Senegal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Réseau Africain de Recherche sur le SIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Réseau Africain de Recherche sur le SIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent breakthroughs in antiretroviral (ARV)-based prevention provide new opportunities to&#xD;
      rethink HIV prevention and treatment strategies, especially for key populations such as&#xD;
      Female Sex Workers (FSWs). Antiretroviral (ARV)-based prevention of HIV transmission has the&#xD;
      potential to have a profound population-level impact on the course of the HIV/AIDS pandemic.&#xD;
      Several recently completed randomized controlled trials of HIV Pre-exposure Prophylaxis&#xD;
      (PrEP) have shown efficacy at reducing HIV acquisition in high-risk populations. How to&#xD;
      translate these trial results into population-level effects is the next critical step. PrEP&#xD;
      &quot;demonstration&quot; projects, in collaboration with local stakeholders and at sites of routine&#xD;
      care for high-risk populations provide an opportunity to move promising research results into&#xD;
      actual public health benefits. With these key features in mind, the investigators propose an&#xD;
      HIV PrEP demonstration project in FSW in Dakar, Senegal, West Africa. The objective of the&#xD;
      proposed demonstration project with Tenofovir DF/Emtricitabine (TDF/FTC) among Female Sex&#xD;
      Workers (FSW) in Dakar Senegal is to build a sustainable HIV PrEP program for FSW in Dakar,&#xD;
      Senegal while demonstrating the feasibility of providing daily oral PrEP with Truvada&#xD;
      (TDF/FTC) for 12 months to the enrolled FSW at Ministry of Heath run clinics (Pikine, Mbao,&#xD;
      Rufisque and Diamniadio Health Centers). Critical milestones for this demonstration project&#xD;
      with be feasibility, uptake, acceptability, use of TDF/FTC PrEP and programmatic retention of&#xD;
      FSWs in Dakar MoH clinics. The investigators have assembled an expert team from RARS,The&#xD;
      University of Washington, and Westat that have had greater than 2 decades of collaboration on&#xD;
      HIV related projects in FSWs in Senegal. The investigators expect the results of this project&#xD;
      will show that Senegal provides a unique opportunity to assess acceptability, feasibility,&#xD;
      uptake and effectiveness of oral HIV PrEP at reducing HIV transmission in a high-risk FSW&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN This is a two-phase study, consisting of the following:&#xD;
&#xD;
      PHASE I - The feasibility evaluation for this study will take several forms.&#xD;
&#xD;
        -  Observations - Field-based assessment of service delivery at each of the five sites;&#xD;
&#xD;
        -  In-depth interviews - With policymakers, program managers, and service providers, as&#xD;
           well as other community members and leaders; and&#xD;
&#xD;
        -  Focus groups with registered and unregistered female sex workers (FSW). PHASE II - This&#xD;
           will be a prospective demonstration study of oral pre-exposure prophylaxis (PrEP) with&#xD;
           Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for FSW with 12 months of follow&#xD;
           up and a 3-month accrual period. A total of 267 FSW will be enrolled.&#xD;
&#xD;
      OBJECTIVES&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        -  Build a sustainable HIV PrEP program for FSW in Dakar, Senegal.&#xD;
&#xD;
        -  Demonstrate the feasibility of providing daily oral PrEP with FTC/TDF for 12 months to&#xD;
           FSW at Ministry of Health (MoH)-run clinics in Pikine, Mbao, Rufisque and Diamniadio&#xD;
           Health Centers) in Dakar.&#xD;
&#xD;
      POPULATION &amp; SAMPLE SIZE&#xD;
&#xD;
      PHASE I:&#xD;
&#xD;
        -  10 Key Informants: Policymakers, program managers, and service providers, as well as&#xD;
           other community members and leaders.&#xD;
&#xD;
        -  Focus Group Participants: 8 Registered and 8 Unregistered HIV-negative FSW age 18 or&#xD;
           older.&#xD;
&#xD;
      PHASE II:&#xD;
&#xD;
      • 267 HIV-negative FSW age 18 or older recruited from four public health centers in Dakar:&#xD;
      Pikine, Mbao, Rufisque and Diamniadio Health Centers.&#xD;
&#xD;
      PROTOCOL EVALUATIONS&#xD;
&#xD;
        -  PHASE I: Qualitative data from observations, key informant interviews, and focus groups&#xD;
           will be collected, analyzed and used to inform the implementation of Phase II.&#xD;
&#xD;
        -  PHASE II: Quantitative data will be collected using behavioral measures and clinical and&#xD;
           laboratory evaluations. Data from electronic monitoring will also be collected.&#xD;
&#xD;
      STUDY DURATION 24 months&#xD;
&#xD;
      REGIMEN Daily oral PrEP with FTC/TDF for 12 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number/proportion of FSWs who remain in the program</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>HIV Pre-exposure Prophylaxis (PrEP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Truvada</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Demonstration Study</description>
    <arm_group_label>HIV Pre-exposure Prophylaxis (PrEP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Completion of the written informed consent process prior to undergoing any screening&#xD;
             evaluations&#xD;
&#xD;
               -  ≥ 18 years and older&#xD;
&#xD;
               -  Active sex work (Paid sex within the past six months)&#xD;
&#xD;
               -  In general good health, confirmed by medical history and physical examination&#xD;
&#xD;
               -  Has laboratory evidence of absence of HIV infection, defined as a negative 4th&#xD;
                  generation HIV ELISA test prior to enrollment&#xD;
&#xD;
               -  Serum creatinine less than or equal to the upper limit of normal (ULN) and&#xD;
                  calculated creatinine clearance of at least 70 mL/minute by Cockcroft-Gault&#xD;
                  formula&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 2.5&#xD;
                  times ULN&#xD;
&#xD;
               -  Hemoglobin greater than 8.5 g/dL&#xD;
&#xD;
               -  Does not report intention to relocate out of the study area during the course of&#xD;
                  the study&#xD;
&#xD;
               -  If able to become pregnant, self-reported use of an effective method of&#xD;
                  contraception at enrollment, and intending to use an effective method during the&#xD;
                  follow-up period&#xD;
&#xD;
               -  Without signs or symptoms of acute HIV infection (acute retroviral syndrome)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • HIV-1 and HIV-2 screening tests are reactive&#xD;
&#xD;
               -  Is enrolled in any other clinical product trial&#xD;
&#xD;
               -  Serious and active medical condition&#xD;
&#xD;
               -  Proteinuria 2+ or greater at screening&#xD;
&#xD;
               -  Glucosuria 2+ or greater at screening&#xD;
&#xD;
               -  Use of disallowed medications (*See note below)&#xD;
&#xD;
               -  Presence of active serious psychiatric symptoms (e.g., active hallucinations,&#xD;
                  suicidal, homicidal, or exhibiting violent behavior) at the time of consent&#xD;
&#xD;
               -  Intoxicated or under the influence of alcohol or other drugs at the time of&#xD;
                  screening&#xD;
&#xD;
               -  Pregnant females and females who are breast-feeding&#xD;
&#xD;
               -  Any other reason or condition that in the opinion of the investigator would&#xD;
                  interfere with participation, complicate interpretation of study outcome data, or&#xD;
                  otherwise interfere with achieving the study objectives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Souleymane Mboup, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RARS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffrey S Gottlieb, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moussa Sarr, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westat</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de santé de Mbao</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Santé de Rufisque</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Santé Dominique de Pikine</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre hospitalier de Diamniadio</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Réseau Africain de Recherche sur le SIDA</investigator_affiliation>
    <investigator_full_name>Souleymane Mboup</investigator_full_name>
    <investigator_title>Director, RARS</investigator_title>
  </responsible_party>
  <keyword>Truvada</keyword>
  <keyword>EMTRICITABINE/TENOFOVIR DISPROXIL FUMARATE</keyword>
  <keyword>HIV PREEXPOSURE PROPHYLAXIS (PrEP)</keyword>
  <keyword>Female Sex Workers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

